Keveyis.com

Keveyis.com has Server used 104.31.95.222 IP Address with Hostname in United States. Below listing website ranking, Similar Webs, Backlinks. This domain was first 2015-07-02 (4 years, 78 days) and hosted in San Francisco United States, server ping response time 8 ms

DNS & Emails Contact

This tool is used to extract the DNS and Emails from this domain uses to contact the customer.

Fetching Emails ...

Extract All Emails from Domain

Top Keywords Suggestions

Keywords suggestion tool used Keveyis keyword to suggest some keywords related from this domain. If you want more, you can press button Load more »

1 Keveyis
2 Keveyis drug
3 Keveyis medication
4 Keveyis cost
5 Keveyis info
6 Keveyis tabs
7 Keveyis use
8 Keveyis wiki
9 Keveyis hcpcs

Hosting Provider

Website: Keveyis.com
Hostname: 104.31.95.222
Country:
Region: CA
City: San Francisco
Postal Code: 94107
Latitude: 37.76969909668
Longitude: -122.39330291748
Area Code: 415
Email AbuseNo Emails Found

Find Other Domains on Any IP/ Domain


New! Domain Extensions Updated .com .org .de .net .uk   » more ...

Domains Actived Recently

Results For Websites Listing

Found 56 Websites with content related to this domain, It is result after search with search engine

KEVEYIS® (dichlorphenamide) | Primary Periodic Paralysis

KEVEYIS can help you gain greater control over the disease by decreasing the number, severity, and duration of attacks. 1,2 KEVEYIS is the only FDA-approved treatment for Primary Periodic Paralysis (PPP), a condition that can cause prolonged attacks of muscle weakness and even temporary paralysis. 1-3 Learn more about KEVEYIS

https://www.keveyis.com/

KEVEYIS® (dichlorphenamide): Treatment for Primary

Please visit www.KEVEYIS.com to view our Important Safety Information and Full Prescribing Information KEVEYIS, granted orphan drug designation in the United States, is the first and only FDA-approved treatment for hyperkalemic, hypokalemic, and related variants of Primary Periodic Paralysis — an ultra-rare neuromuscular disorder.1 KEVEYIS Has Been Proven to Reduce Attacks in 2 Clinical

https://www.strongbridgebio.com/products/keveyis/

Strongbridge Biopharma plc Presents KEVEYIS

For additional KEVEYIS important safety information and the full prescribing information visit www.keveyis.com. Contacts: Corporate and Media Relations Elixir Health Public Relations Lindsay Rocco +1 862-596-1304 [email protected] Investor Relations U.S.: Solebury Trout Marcy Nanus +1 646-378-2927 [email protected] Europe: First House Geir Arne

https://investors.strongbridgebio.com/news-releases/news-release-details/strongbridge-biopharma-plc-presents-keveyisr-dichlorphenamide

Strongbridge Biopharma plc Presents KEVEYIS

Strongbridge Biopharma plc Presents KEVEYIS® (dichlorphenamide) Primary Periodic Paralysis (PPP) Data at the 2019 American Academy of Neurology Annual Meeting

https://www.globenewswire.com/news-release/2019/05/09/1821337/0/en/Strongbridge-Biopharma-plc-Presents-KEVEYIS-dichlorphenamide-Primary-Periodic-Paralysis-PPP-Data-at-the-2019-American-Academy-of-Neurology-Annual-Meeting.html

Strongbridge Biopharma plc Presents KEVEYIS

~ Results Demonstrate Long-term Treatment with KEVEYIS is Efficacious and Provides Durable Reduction in Attack Frequency and Severity in Patients with PPP ~ DUBLIN, Ireland and.

https://finance.yahoo.com/news/strongbridge-biopharma-plc-presents-keveyis-200500346.html

Keveyis.us - WHOIS & Domain Info - DomainBigData

keveyis.us is hosted in Lansing, Michigan, United States and is owned by Taro Domain Manager (Taro Pharmaceuticals U.s.a. Inc). keveyis.us was created on 2015-07-28. Website IP is 98.129.229.210

https://domainbigdata.com/keveyis.us

Taro to Make Keveyis™ Available to Distributors Free of

For additional safety information, please see Full Prescribing Information at www.keveyis.com. The release will be accessible on Taro’s website at www.taro.com. About Taro

https://www.businesswire.com/news/home/20160502005639/en/Taro-Keveyis™-Distributors-Free-Cost

FDA Approves Drug for Primary Hyperkalemic and Hypokalemic

Statement from MDA Executive Vice President and Chief Medical and Scientific Officer Valerie A. Cwik, M.D.: “We couldn’t be more pleased for our families affected by hyperkalemic and hypokalemic periodic paralysis, as the first treatment for these diseases has been approved by the U.S. Food and Drug Administration (FDA) and is expected to be available in the coming months.”

https://strongly.mda.org/fda-approves-drug-for-primary-hyperkalemic-and-hypokalemic-periodic-paralysis/

FDA Approves Taro’s Keveyis™ (dichlorphenamide) 50 mg

HAWTHORNE, N.Y.--(BUSINESS WIRE)--Taro Pharmaceutical Industries Ltd. (NYSE:TARO) announced today that the U.S. Food and Drug Administration (FDA) has approved Keveyis™ (dichlorphenamide) 50 mg

https://www.businesswire.com/news/home/20150810005655/en/FDA-Approves-Taro’s-Keveyis™-dichlorphenamide-50-mg

Recently Analyzed Sites